Study: Generic Drug Industry Embraces Faster, Cheaper Pathway For Challenging Patents
From the article:
A newly released study shows that generic drug companies win nearly half the time when challenging patents on United States government-approved pharmaceutical products through the Patent Trial and Appeal Board (PTAB) process.
The study, entitled, “The Generic Drug Industry Embraces a Faster, Cheaper Pathway for Challenging Patents,” was published in “Applied Health Economics and Health Policy.” The authors are: Jonathan J. Darrow, S.J.D., J.D., M.B.A., Reed F. Beall, Ph.D., and Aaron S. Kesselheim M.D., J.D., M.P.H.